Avusturya - Almanca - AGES (Agentur für Gesundheit und Ernährungssicherheit)

galenpharma gmbh - testosteron -

Avusturya - Almanca - AGES (Agentur für Gesundheit und Ernährungssicherheit)

actavis group ptc ehf - carboplatin - carboplatin

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hämoglobinurie, paroxysmal - selektive immunsuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - antianämische präparate - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

amgen technology (ireland) uc - eculizumab - hämoglobinurie, paroxysmal - immunsuppressiva - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). klinischer nutzen ist nachgewiesen bei patienten mit hämolyse mit klinischen symptom(s) indikativ von hoher krankheitsaktivität unabhängig von der transfusion geschichte (siehe abschnitt 5.

Avusturya - Almanca - AGES (Agentur für Gesundheit und Ernährungssicherheit)

b. braun melsungen ag - natriumchlorid; polygelin - gelatine-haltige mittel

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ceva tiergesundheit gmbh (3123507) - gleptoferron ((mit angaben zur zusammensetzung)) - injektionslösung - gleptoferron ((mit angaben zur zusammensetzung)) (18964) 493 milligramm - saugferkel

Avusturya - Almanca - AGES (Agentur für Gesundheit und Ernährungssicherheit)

g.l. pharma gmbh - pioglitazon hydrochlorid -

Avusturya - Almanca - AGES (Agentur für Gesundheit und Ernährungssicherheit)

g.l. pharma gmbh - pioglitazon hydrochlorid -

Avusturya - Almanca - AGES (Agentur für Gesundheit und Ernährungssicherheit)

g.l. pharma gmbh - pioglitazon hydrochlorid -